Diffusion-weighted imaging in Huntington's disease

Movement Disorders

Volumn 21, Issue 7, 2006, Pages 1043-1047

  Seppi, Klaus ^a   Schocke, Michael F H ^a   Mair, Katherina J ^a   Esterhammer, Regina ^a   Weirich Schwaiger, Helga ^a   Utermann, Barbara ^a   Egger, Karl ^a   Brenneis, Christian ^a   Granata, Roberta ^a   Boesch, Sylvia ^a   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Diffusion weighted imaging; Huntington's disease; Magnetic resonance imaging; Striatum

Indexed keywords

ADENINE; CYTOSINE; GUANINE; HUNTINGTIN;

ADULT; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEVICE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PUTAMEN; THALAMUS; TRINUCLEOTIDE REPEAT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; BASAL GANGLIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; THALAMUS;

EID: 33746904273     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20868     Document Type: Article

References (36)

1. Biglan KM, Shoulson I. Huntington's disease. In: Jankovic JJ, Tolosa E, editors. Parkinson's disease and movement disorders. Philadelphia: Lippincott Williams and Wilkins; 2002. p 212-227.
2. Mascalchi M, Lolli F, Della NR, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867-873.
3. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency - Huntington Study Group. Mov Disord 1996;11:136-142.
4. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981; 31:1333-1335.
5. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994;44:1533-1536.
6. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes 1993;7:235-239.
7. Laccone F, Engel U, Holinski-Feder E, et al. DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland. Neurology 1999;53:801-806.
8. Holzmann C, Saecker AM, Epplen JT, Riess O. Avoiding errors in the diagnosis of (CAG)n expansion in the huntingtin gene. J Med Genet 1997;34:264.
9. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
10. Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 2004;21:1443-1451.
11. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
12. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio AA, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812.
13. Rosas HD, Goodman J, Chen YI, et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025-1028.
14. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
15. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
16. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996;11: 167-173.
17. Harris GJ, Aylward EH, Peyser CE, et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 1996;53:316-324.
18. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord 1986;1:69-77.
19. Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-255.
20. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003;4:469-480.
21. Seppi K, Schocke MF, Donnemiller E, et al. Comparison of diffusion-weighted imaging and [(123)I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord 2004; 19:1438-1445.
22. Horsfield MA, Jones DK. Applications of diffusion-weighted and diffusion tensor MRI to white matter diseases: a review. NMR Biomed 2002;15:570-577.
23. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
24. Chun T, Filippi CG, Zimmerman RD, Ulug AM. Diffusion changes in the aging human brain. Am J Neuroradiol 2000;21: 1078-1083.
25. Helenius J, Soinne L, Perkio J, et al. Diffusion-weighted MR imaging in normal human brains in various age groups. Am J Neuroradiol 2002;23:194-199.
26. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-384.
27. Hayden MR, Martin WR, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986;36:888-894.
28. Aylward EH, Schwartz J, Machlin S, Pearlson G. Bicaudate ratio as a measure of caudate volume on MR images. Am J Neuroradiol 1991;12:1217-1222.
29. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119(Pt. 6):2085-2095.
30. Starkstein SE, Brandt J, Folstein S, et al. Neuropsychological and neuroradiological correlates in Huntington's disease. J Neurol Neurosurg Psychiatry 1988;51:1259-1263.
31. Schaefer PW. Applications of DWI in clinical neurology. J Neurol Sci 2001;186(Suppl. 1):S25-S35.
32. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407-1419.
33. Mascalchi M, Moretti M, Della NR, et al. Longitudinal evaluation of leukoaraiosis with whole brain ADC histograms. Neurology 2002;59:938-940.
34. Mitchell IJ, Cooper AJ, Griffiths MR. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999;59:691-719.
35. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol (Berl) 1999;97:613-622.
36. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996; 39:132-136.